{"relation": [["", "EDTA + High Dose Vitamin", "EDTA + High Dose Vitamin Placebo", "EDTA Placebo + High Dose Vitamin", "EDTA Placebo + High Dose Vitamin Placebo", "Total"], ["Description", "Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.", "Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.", "Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.", "Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.", "Total of all reporting groups"]], "pageTitle": "Trial to Assess Chelation Therapy (TACT) - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00044213?sect=X701&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 6, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043062723.96/warc/CC-MAIN-20150728002422-00083-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 869875233, "recordOffset": 869867031, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details The primary analysis of the trial included 1708 patients who had been enrolled from September 2003 through October 2011 (median, 55 months)Participants were recruited at 134 sites in the US and Canada. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: EDTA Drug: EDTA Placebo Dietary Supplement: High Dose Vitamin Dietary Supplement: High Dose Vitamin Placebo Interventions: Coronary Artery Disease Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Factorial\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design:", "textAfterTable": "\u00a0 \u00a0 EDTA + High Dose Vitamin \u00a0 \u00a0 EDTA + High Dose Vitamin Placebo \u00a0 \u00a0 EDTA Placebo + High Dose Vitamin \u00a0 \u00a0 EDTA Placebo + High Dose Vitamin Placebo \u00a0 STARTED \u00a0 \u00a0 421 \u00a0 \u00a0 418 \u00a0 \u00a0 432 \u00a0 \u00a0 437 \u00a0 COMPLETED \u00a0 \u00a0 321 \u00a0 \u00a0 306 \u00a0 \u00a0 294 \u00a0 \u00a0 301 \u00a0 NOT COMPLETED \u00a0 \u00a0 100 \u00a0 \u00a0 112 \u00a0 \u00a0 138 \u00a0 \u00a0 136 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 50 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 65 \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}